Innovation
In the 2022/2023 business year, we spent EUR 48 million on research and development

Egis' medicines won the Innovation Grand Prize
Two of Egis’ fixed-dose combination drugs have won the Innovation Grand Prize. The awarded Egis medicines feature significant innovations as they reduce the risk of cardiovascular events related to atherosclerosis due to the combined lipid-lowering therapy. In respect of these two products the company obtained three patents related to active ingredient development and two patents related to formulation development that are all relevant to large-scale manufacturing technologies. The recognition was not without a history, as this is the tenth time an Egis medicine has received an Innovation Prize or Grand Prize. More

Our project aimed at developing oncological active ingredients and preparations has concluded successfully

Over the past four years, our company has made significant progress in the field of oncological active ingredient and preparation development, thanks to the support received through the project titled ´Development of innovative, high added value oncological drug preparations for personalized therapies.´ During the period from 2021 to 2024, we worked on the development of 14 active ingredients and 5 preparations in collaboration with our consortium partner, HUN-REN TTK. More

Development of Innovative, High Value-Added Oncological Drug Products for Personalized Therapies

he project identified as 2020-1.1.2-PIACI-KFI-2020-00039, conducted by Egis Pharmaceuticals PLC and its consortium partner, the HUN-REN Research Centre for Natural Sciences (TTK), finished on December 31, 2024. More

Egis expands its portfolio with active pharmaceutical ingredient contract development and contract manufacturing

Egis Pharmaceuticals PLC, celebrating the 110th anniversary of its foundation this year, is expanding its usual activities with new elements thanks to investments exceeding a total value of more than HUF 100 billion in Hungary over the past decade.  Egis, one of the leading generic pharmaceutical companies in Eastern and Central Europe, now offers drug substance contract development and contract manufacturing services under the name of Egis Pharma Services to both existing and new pharmaceutical partners.

More

Egis Inaugurates Two New Plants in Körmend

Two technology-intensive developments, carried out with state subsidies, were completed at Egis Pharmaceuticals PLC’s Körmend site (Hungary). The investments were inaugurated by Péter Szijjártó, Minister of Foreign Affairs and Trade, and by the company’s CEO, Dr. István Hodász on 15 October.  In addition to a new packaging plant, Egis has also established a plant with special knowledge and technology requirements, typically suitable to manufacture oncology products.  Thus, Egis is now able to implement all value-creating processes within the field of oncology, from development to active ingredient and finished product manufacturing.

More

Study on Neuroscience Research wins Egis’ Prize this Year

As research and development are fundamental pillars of our strategy Egis is deeply committed to raise students’ interest in science and help the promising young minds develop their talents. That is why we have been supporting the annual ’Scientific and Innovation Talent Recruitment Contest for Youth’ for decades. This year, Egis’ prize went to undergraduate student Hunor Sebők.

More

Strategic cooperation agreement between Semmelweis University and Egis

The Semmelweis University and Egis Pharmaceuticals PLC have agreed on an even closer cooperation than before. Our common goal is to further raise the standards of pharmaceutical R+D as well as pharmacist and doctor training by making use of the synergies in each other’s activities. As a result of the agreement, new health industrial innovations can be launched and the Semmelweis University can be extended with more practical educational and training elements that also meet the needs of the Hungarian pharmaceutical industry.

More
Other channels
Egis World
Egis´ products are sold to more than 100 countries.
Our People
Our mission is to serve people with all of our skills, ensuring that they live a long and healthy life
Health
The company’s product portfolio consisted of more than 650 products
Corporate Social Responsibility
Healthcare and sharing knowledge are in the heart of our CSR activities
Events
Our highlighted past and future events you shouldn't miss

Cookie Settings

Egis’s website uses cookies to run our website, improve the user experience and monitor the activities. You can customize the use of the cookies by adapting the settings.

Cookies necessary for basic functioning

These cookies ensure the appropriate functioning of the website, facilitate its use and collect information on its use without identifying visitors.

Functional cookies

In order to enhance the user experience, we use cookies which record the use of certain functions of the website, thus enabling users to have the same settings at the time of their next visit.

Cookies for statistical purposes

They provide statistical data on the performance of the website (such as number of page loads, average time spent on the website) in order to collect data for the operator of the website on the website usage patterns of users. These cookies do not identify visitors, information collected by them relate to the number of subpages visited by the user, the length of each session, the types of error messages, etc. Cookies for statistical purposes are automatically placed on the user’s devices during browsing, and you can delete such cookies in the browser settings.
Details
I Agree
WarningYour browser is out of date. Please, use an updated version! Chrome || Firefox